- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Locally advanced or metastatic non-small cell lung cancer (NSCLC)
- Meeting Date: July 2023
- Public Summary Document (PSD) July 2023 PBAC Meeting - (PDF 1.1MB)
- Public Summary Document (PSD) July 2023 PBAC Meeting - (Word 543KB)
Mobocertinib – July 2023
Mobocertinib: Capsule 40 mg; Exkivity®
Last updated
27 October 2023